Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Primed Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$455,106

241 payments

Through program year 2025, Primed Clinical Research is reported as receiving $455,106 in research payments, across 241 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $143,252 26
2024 Research $161,663 186
2023 Research $6,400 1
2022 Research $13,619 7
2021 Research $102,188 2
2020 Research $22,909 8
2019 Research $5,076 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $199,214 6 payments
  2. Novo Nordisk AS $119,977 187 payments
  3. Merck Sharp & Dohme Corporation $96,726 6 payments
  4. GlaxoSmithKline, LLC. $17,300 1 payment
  5. Sanofi US Services Inc. $12,420 21 payments
  6. Amgen Inc. $7,917 6 payments
  7. Pfizer Inc. $1,552 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $153,514 2 payments
  2. Nn9536-7752 $119,977 187 payments
  3. A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $89,999 2 payments
  4. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $45,700 4 payments
  5. A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $17,300 1 payment
  6. A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States $12,420 21 payments
  7. A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $6,426 2 payments
  8. Galactic-Hf $4,775 3 payments
  9. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $1,703 1 payment
  10. Galactic - HF $1,438 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record